Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
Park RJ, Parikh M, Pappas L, Sade-Feldman M, Kulkarni AS, Bi L, LaSalle TJ, Galway A, Kuhlman C, Blaszkowsky LS, Meyerhardt JA, Enzinger PC, Biller L, Allen JN, Kagey MH, Baum J, Sirard C, Duda DG, Zhu AX, Abrams TA, Hacohen N, Ting DT, Mehta A, Goyal L.
Park RJ, et al. Among authors: kuhlman c.
medRxiv [Preprint]. 2024 Oct 8:2024.10.08.24315092. doi: 10.1101/2024.10.08.24315092.
medRxiv. 2024.
PMID: 39417106
Free PMC article.
Preprint.